Financial Performance - The company's operating revenue for Q1 2025 was ¥98,432,423.04, representing a 28.69% increase compared to ¥76,490,637.69 in the same period last year[4] - Net profit attributable to shareholders for Q1 2025 was ¥39,321,956.98, up 47.70% from ¥26,623,641.96 in the previous year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,958,544.46, reflecting a 58.78% increase from ¥23,276,483.10 year-over-year[8] - Basic and diluted earnings per share for Q1 2025 were both ¥0.10, representing a 42.86% increase from ¥0.07 in the same period last year[8] - Total operating revenue for the current period reached ¥98,432,423.04, an increase of 28.7% compared to ¥76,490,637.69 in the previous period[20] - Net profit for the current period was ¥39,321,956.98, representing a significant increase of 47.8% from ¥26,623,641.96 in the previous period[21] - Basic and diluted earnings per share improved to ¥0.10 from ¥0.07, reflecting a growth of 42.9%[22] Cash Flow and Liquidity - The net cash flow from operating activities was ¥38,039,030.13, a 53.69% increase compared to ¥24,750,149.18 in the same period last year[4] - Operating cash inflow for the current period reached $125,931,740.21, a significant increase from $86,704,603.35 in the previous period, representing a growth of approximately 45.2%[24] - Net cash flow from operating activities amounted to $38,039,030.13, up from $24,750,149.18, indicating a year-over-year increase of about 53.4%[25] - The net increase in cash and cash equivalents for the period was $412,920,478.03, compared to $17,115,295.83 in the previous period, showing a substantial increase[25] - The ending balance of cash and cash equivalents reached $615,399,581.57, significantly higher than $111,656,417.50 at the end of the previous period[25] - The company reported cash receipts from operating activities, including tax refunds of $5,496,002.09, which is a notable increase from $1,130,548.50[24] Assets and Liabilities - Total assets at the end of Q1 2025 reached ¥1,412,092,153.94, a 40.36% increase from ¥1,006,037,837.71 at the end of the previous year[4] - Total current assets increased to 1,292,025,161.15 RMB from 879,665,743.61 RMB, representing a growth of approximately 47%[16] - The total assets increased to ¥1,412,092,153.94 from ¥1,006,037,837.71, marking a growth of 40.4%[18] - The total liabilities decreased to ¥118,511,582.72 from ¥135,377,063.86, a reduction of 12.4%[18] Shareholder Information - Shareholders' equity attributable to the company was ¥1,293,580,571.22, up 48.57% from ¥870,660,773.85 at the end of the previous year[4] - The largest shareholder, Shantou Ultrasonic Asset Management Co., holds 51.32% of shares, totaling 219,830,247 shares[10] - The second largest shareholder, Shantou Municipal Government State-owned Assets Supervision and Administration Commission, holds 31.14% of shares, totaling 133,369,945 shares[10] - Total number of common shareholders at the end of the reporting period is 26,755[10] Expenses and Costs - Total operating costs amounted to ¥57,345,176.36, up from ¥50,601,040.15, reflecting a growth of 13.4%[20] - The company experienced a 34.17% increase in management expenses, totaling ¥9,444,052.87, primarily due to increased consulting and meeting costs[7] - Research and development expenses for the current period were ¥11,476,627.29, compared to ¥10,391,176.86 in the previous period, indicating a rise of 10.4%[20] Cash and Investment Activities - Cash inflow from investment activities totaled $634,041,047.55, compared to $397,976,180.06 in the prior period, reflecting a growth of approximately 59.2%[25] - Cash outflow from investment activities was $646,329,625.52, which is an increase from $405,639,488.18, resulting in a net cash flow from investment activities of -$12,288,577.97[25] - Cash inflow from financing activities was $401,633,651.91, with cash outflow totaling $14,404,923.00, leading to a net cash flow from financing activities of $387,228,728.91[25] - The company received $632,276,812.55 in cash from investment recoveries, up from $395,183,873.76, marking an increase of approximately 60%[25] Other Information - The company received government subsidies amounting to ¥583,185.04, which are closely related to its normal business operations[5] - The company has no changes in the number of restricted shares for major shareholders during the reporting period[13] - The total number of restricted shares remains at 364,080,192, with no shares released during the period[14] - The company has not disclosed any new product developments or market expansion strategies in the current report[15] - The cash flow statement will provide insights into the company's liquidity and operational efficiency, with further details to be disclosed[23] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[22]

Dividend Distribution - The company plans to distribute a cash dividend of 1.02 RMB per 10 shares (including tax) to all shareholders[4]. - The company will not issue any bonus shares as part of the profit distribution plan[4]. - The board of directors has approved the profit distribution plan during the meeting[4]. - The cash dividend amount accounts for 100% of the total profit distribution, with no other forms of cash distribution such as share buybacks[191]. - The cash dividend policy aligns with the company's articles of association and shareholder meeting resolutions, ensuring transparency and compliance[191]. - The cash dividend distribution is based on the actual operational needs and long-term development plans of the company[192]. Financial Performance - The company's operating revenue for 2024 reached ¥375,813,223.81, representing a 15.09% increase compared to ¥326,542,857.93 in 2023[20]. - Net profit attributable to shareholders for 2024 was ¥145,577,556.51, a 26.12% increase from ¥115,427,511.56 in 2023[20]. - The net profit after deducting non-recurring gains and losses was ¥136,263,774.66, up 33.09% from ¥102,381,917.91 in 2023[20]. - Cash flow from operating activities for 2024 was ¥132,394,299.90, an increase of 80.33% compared to ¥73,416,726.11 in 2023[20]. - Basic earnings per share for 2024 were ¥0.40, a 25.00% increase from ¥0.32 in 2023[20]. - Total assets at the end of 2024 amounted to ¥1,006,037,837.71, reflecting a 19.85% increase from ¥839,422,579.64 at the end of 2023[20]. - Net assets attributable to shareholders increased by 20.30% to ¥870,660,773.85 at the end of 2024 from ¥723,766,407.95 at the end of 2023[20]. - The company reported a quarterly revenue of ¥114,642,683.53 in Q4 2024, showing consistent growth throughout the year[22]. Risk Management - The report emphasizes the importance of understanding the risks associated with future plans and strategies[4]. - The company has outlined potential risk factors and countermeasures in the management discussion section[4]. - The company faces risks from industry regulations and policy changes, particularly in the medical device sector, which could impact market access and financial performance[129]. - Currency exchange rate fluctuations pose a risk to the company's overseas revenue, which is primarily settled in USD and EUR, potentially affecting sales and profit margins[130]. - International trade tensions, such as US-China trade friction, may introduce uncertainties in overseas markets, affecting business expansion and supply chain stability[131]. Research and Development - The company has established multiple R&D centers, including in Shantou, Xi'an, Guangzhou, and Seattle, focusing on advanced imaging technologies and cloud-based software systems[43]. - The R&D team comprises 115 personnel, representing 15.21% of total employees, with core technical staff accounting for 10.43% of the R&D team[46]. - R&D expenses accounted for 13.32% of total revenue, maintaining a stable level above 10% for several consecutive years[51]. - The company is developing a portable low-radiation artificial intelligence DR imaging diagnostic system to enhance diagnostic efficiency and product competitiveness, with prototype testing and software design in progress[69]. - The company is focusing on the application and expansion of multimodal products in the emergency rescue field, enhancing features such as vital signs monitoring and AI-assisted diagnosis[125]. Product Development and Market Expansion - The company is a pioneer in the domestic ultrasound diagnosis and testing industry, with significant advancements in various technologies such as color Doppler ultrasound imaging systems and industrial ultrasonic testing instruments[31]. - The medical ultrasound imaging equipment market is expanding, driven by smart and innovative technologies, with a focus on portable devices and AI integration[29]. - The company aims to deepen domestic market penetration while expanding into emerging markets along the Belt and Road Initiative[29]. - The company has developed a portable DR device with a built-in high-capacity battery, marking a significant innovation in the industry[34]. - The company is actively pursuing regulatory approvals for new products, with several registrations in 2023, indicating a proactive approach to market expansion[95]. Governance and Compliance - The company has established a robust information disclosure management system to enhance transparency and protect shareholder rights[142]. - The company's governance practices align with legal and regulatory standards, with no significant discrepancies identified[144]. - The company has established an independent financial department with a complete accounting system, ensuring no shared bank accounts with the controlling shareholder[146]. - The company has a complete and independent asset structure, with no reliance on the controlling shareholder's assets for operations[145]. - The company has maintained effective internal controls without any major deficiencies affecting the evaluation conclusion during the reporting period[196]. Employee Management - The total number of employees at the end of the reporting period is 756, with 669 from the parent company and 87 from major subsidiaries[186]. - The company has established a comprehensive employee compensation and benefits management system to enhance employee satisfaction and loyalty[187]. - Training programs are aligned with the company's development strategy, focusing on enhancing management and key personnel's strategic analysis and management capabilities[188]. - The company is committed to enhancing its human resources planning and incentive mechanisms to attract and retain top talent[135]. Financial Strategy - The company plans to invest approximately 240 million CNY in new fixed and intangible assets, leading to an annual increase in depreciation and amortization of about 40 million CNY[133]. - The company will continue to support distributors through training, technical support, and marketing activities to ensure sustained sales revenue growth[133]. - The company has no significant equity investments or securities investments during the reporting period, indicating a conservative investment strategy[114]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan allocated for potential deals[174].

超研股份（301602）公告，公司于2025年4月27日召开的第二届董事会第八次会议上，审议通过了向全 资子公司深圳汕超增资的议案。公司计划以自有资金人民币50万元增资深圳汕超。增资完成后，深圳汕 超的注册资本将由人民币50万元增加至人民币100万元，仍为公司全资子公司。本次增资旨在支持深圳 汕超的业务发展，不涉及关联交易或重大资产重组，不需提交股东会审议。增资预计不会对公司财务状 况和经营成果产生重大影响。 ...

一、本次增资事项概述 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于2025 年4月27日召开第二届董事会第八次会议，审议通过了《关于向子公 司增资的议案》，根据公司的发展战略和全资子公司深圳市汕超科技 有限公司（以下简称"深圳汕超"）的经营管理需要，公司拟以自有 资金人民币50万元对深圳汕超进行增资。本次增资完成后，深圳汕超 的注册资本由人民币50万元增加至人民币100万元，仍为公司全资子 公司。 根据《深圳证券交易所创业板股票上市规则（2024 年修订）》和 《公司章程》等相关规定，本次对外投资在公司董事会审议权限内， 无需提交公司股东会审议。本次对外投资不构成关联交易，也不构成 《上市公司重大资产重组管理办法》规定的重大资产重组。 二、增资标的基本情况 1、公司名称：深圳市汕超科技有限公司 证券代码：301602 证券简称：超研股份 公告编号：2025-018 汕头市超声仪器研究所股份有限公司 关于向子公司增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 2、成立日期：2015年10月26日 3、注册地址：深圳市福田区梅林街道中康路12 ...

证券代码：301602 证券简称：超研股份 公告编号：2025-009 汕头市超声仪器研究所股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 3、类型：股份有限公司（上市） 4、法定代表人：李德来 5、注册资本：人民币 428,329,638 元 一、工商变更登记情况 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于 2025 年 2 月 13 日召开第二届董事会第七次会议审议通过了《关于修 订上市后适用的〈公司章程〉并提交工商备案的议案》《关于因上市 变更公司注册资本、公司类型并办理工商变更登记的议案》，并于 2025 年 3 月 3 日召开 2025 年第一次临时股东会审议通过上述两项议 案，具体内容详见公司于巨潮资讯网（http://www.cninfo.com.cn） 披露的相关公告。 近日，公司就上述事项办理完成工商变更登记手续及《公司章程》 备案手续，取得了汕头市市场监督管理局核发的《营业执照》，现将 新取得《营业执照》的基本信息公告如下： 1、统一社会信用代码：9144050045594 ...

医药生物行业 增持（首次） 国内超声诊断和检测行业的先行者 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： xiexiongxiong@dgzq.com.cn | 主要数据 2025 年 3 月 | 19 | 日 | | --- | --- | --- | | 收盘价（元） 27.15 | | | | 总市值（亿元） 116.29 | | | | 总股本（亿股） 4.28 | | | | 流通股本（亿股）0.55 | | | | ROE(TTM) 15.16% | | | | 12 月最高价（元）32.10 | | | | 12 月最低价（元）21.60 | | | 股价走势 资料来源：东莞证券研究所，iFind 相关报告 投资要点： ◼ 风险提示。新产品的市场开拓风险、原材料采购风险、行业监管及政 策变化风险和国际贸易摩擦风险等。 超研股份（301602）深度报告 2025 年 3 月 20 日 公 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明 ...

北 京 上 海 深 圳 杭 州 广 州 昆 明 天 津 成 都 宁 波 福 州 西 安 南 京 南 宁 济 南 重 庆 苏 州 长 沙 太 原 武 汉 贵 阳 乌鲁木齐 郑 州 石家庄 合 肥 海 南 青 岛 南 昌 香 港 巴 黎 马德里 斯德哥尔摩 纽 约 广州市天河区华夏路 32 号太平洋金融大厦 19 楼 邮编：510620 电话：(+86)(20) 3879 9346 、38799348 传真：(+86)(20) 3879 9348-200 国浩律师(广州)事务所 关于汕头市超声仪器研究所股份有限公司 2025 年第一次临时股东会的法律意见 汕头市超声仪器研究所股份有限公司： 根据中国证券监督管理委员会发布的《上市公司股东大会规则》(以下简称 《股东大会规则》)的要求，国浩律师(广州)事务所(以下简称"本所")接受汕 头市超声仪器研究所股份有限公司(以下简称"超研股份")的委托，指派程秉、 周姗姗律师(以下简称"本所律师")出席超研股份 2025 年第一次临时股东会(以 下简称"本次股东会")，对本次股东会的召集与召开程序、出席会议人员与召 集人的资格、表决程序与表决结果等重要事项出具法律意见。 本 ...

证券代码：301602 证券简称：超研股份 公告编号：2025-008 汕头市超声仪器研究所股份有限公司 2025年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一） 召开情况 1、会议召开时间： （1）现场会议：2025年3月3日（星期一）下午15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的 时间为2025年3月3日上午9:15-9:25，9:30-11:30，下午13:00-15:00； 通过深圳证券交易所互联网系统投票的具体时间为2025年3月3日 9:15-15:00期间的任意时间。 2、现场会议召开地点：广东省汕头市金砂路77号汕头市超声仪 器研究所股份有限公司101会议室 3、召开方式：本次股东会采取现场投票与网络投票相结合的表 决方式。 4、召集人：汕头市超声仪器研究所股份有限公司董事会 5、主持人：董事长李德来先生 6、会议的召开符合相关法律、行政法规、部门规章、规范性文 ...

答：研发方向是多功能化、专科化、辅助诊疗、便携化、 多模态融合以及信息化和智能化等方向。公司有超过 100 人的 研发团队。主要的研发负责人的背景如下：公司董事长兼总经 理李德来先生系享受国务院特殊津贴专家，教授级高级工程 师，从事医学影像技术、无损检测技术研究及产品研发超过四 十年。常务副总经理杨金耀先生系享受国务院特殊津贴专家， 教授级高级工程师，专注超声仪器总体设计和软件系统设计超 过三十年。副总经理 Liexiang FAN （范列湘）博士系医学影像 学专家，研究和创新的范围包括超声信号的发射和接收及合 成，信号处理，图像重构，新信息提取，智能图像处理和识别， 超声在诊断和治疗的临床应用。总工程师李斌先生系高级工程 师，主导医学超声成像诊断系统从换能器、前端收发、数字信 号处理到图像处理与重建等方面的核心关键技术研发工作。 证券代码：301602 证券简称：超研股份 汕头市超声仪器研究所股份有限公司 投资者关系活动记录表 编号：2025-001 | | ☑特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演 ...

证券代码：301602 证券简称：超研股份 公告编号：2025- 007 汕头市超声仪器研究所股份有限公司 股票交易异常波动公告 6、公司不存在违反信息公平披露的情形。 二、公司关注并核实情况的说明 针对公司股票异常波动情况，公司董事会对公司、控股股东及实 际控制人就相关事项进行了核实，有关情况说明如下： 1、公司未发现前期披露的信息存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了与公司相关且市场关注度较 高的信息。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 3、本公司已披露的经营情况、内外部经营环境未发生重大变化。 一、股票交易异常波动的具体情况 4、经核查，公司、控股股东和实际控制人不存在关于本公司的 应披露而未披露的重大事项，或处于筹划阶段的重大事项。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）股票 交易价格于 2025 年 2 月 14 日、2025 年 2 月 17 日连续两个交易日收 盘价格涨幅偏离值累计超过 30%，根据《深圳证券交易所交易规则》， 属于股票异常波动的情形。 5、经核查，股票异常波动期间公司控股股东、实际 ...